Importantly, treatment with a combination of anti-TGF-β and anti-PD-1 enhanced the CD8+ T cells response against EGFR-mutant NSCLC tumors when compared with treatment with anti-PD-1 alone. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.